TY - JOUR T1 - COVID-19 serological survey using micro blood sampling JF - medRxiv DO - 10.1101/2020.10.09.20209858 SP - 2020.10.09.20209858 AU - Melissa M. Matthews AU - Tae Gyun Kim AU - Satoshi Shibata AU - Noriko Shibata AU - Christian Butcher AU - Jaekyung Hyun AU - Keon Young Kim AU - Theodore Robb AU - Siang Sheng Jheng AU - Masashi Narita AU - Tomoari Mori AU - Mary Collins AU - Matthias Wolf Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/13/2020.10.09.20209858.abstract N2 - During August 2020, we carried out a serological survey among students and employees at the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing for the presence of antibodies against SARS-CoV-2, the causative agent of COVID-19. We used a FDA-authorized 2-step ELISA protocol developed by the Krammer Lab (1, 2) in combination with at-home self-collection of blood samples using a custom low-cost finger prick-based capillary blood collection kit. Although our survey did not find any COVID-19 seropositive individuals among the OIST cohort, it reliably detected all positive control samples obtained from a local hospital and excluded all negatives controls. Among our controls, we found strong cross-reactivity of antibodies in samples from a serum pool from two MERS patients in the anti-SARS-CoV-2-S ELISA. Here we show that a centralized ELISA in combination with patient-based capillary blood collection using as little as one drop of blood can reliably assess the seroprevalence among communities. Anonymous sample tracking and an integrated website created a stream-lined procedure. Major parts of the workflow were automated on a liquid handler, demonstrating scalability. We anticipate this concept to serve as a prototype for reliable serological testing among larger populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Platform Project for Supporting Drug Discovery and Life Science Research (BINDS) from AMED, under grant number JP18am0101076 (to M.W.). We acknowledge financial support by OPG for a larger serological study, as well as direct funding from OIST.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subject research approval: The experiments were conducted according to a proposal approved by the OIST human subjects ethics committee (application HSR-2020-026). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for further information or raw data should be directed to the corresponding author. ER -